SS-31 (Elamipretide).
A mitochondria-targeted peptide for cellular energy and oxidative protection.
Pricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Patients with low cellular energy or chronic fatigue
- Patients wanting better muscle endurance and recovery
- Patients pursuing cardiovascular or neurologic resilience
- Patients focused on anti-aging and metabolic optimization
This isn't for you if
Investigational. Specialist supervision required.
SS-31 (Elamipretide)
SS-31, also known as Elamipretide, is a specialized mitochondria-targeting peptide. It penetrates deep into the mitochondria to reduce oxidative damage, stabilize cardiolipin (a key mitochondrial lipid), and improve ATP production.
Mechanism and fit.
SS-31 binds directly to the inner mitochondrial membrane, protecting it from oxidative stress and supporting efficient energy production. This improves cellular endurance and may support heart, neurologic, and metabolic resilience.
Who this is typically for.
- Patients with low cellular energy or chronic fatigue
- Patients wanting better muscle endurance and recovery
- Patients pursuing cardiovascular or neurologic resilience
- Patients focused on anti-aging and metabolic optimization
What patients
most often ask.
What makes SS-31 different from other mitochondrial peptides?
SS-31 binds directly to cardiolipin in the inner mitochondrial membrane, protecting it from oxidative damage. This direct membrane-stabilizing action is what distinguishes it from broader mitochondrial-support peptides.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Patients with low cellular energy or chronic fatigue</li><li>Patients wanting better muscle endurance and recovery</li><li>Patients pursuing cardiovascular or neurologic resilience</li><li>Patients focused on anti-aging and metabolic optimization</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingProvider-directed; injection-based.
- Typical durationProvider-directed cycles.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering SS-31 (Elamipretide), the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.